According to Karyopharm Therapeutics
's latest financial reports the company has โน11.55 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | โน15.93 B | -30.71% |
2022-12-31 | โน23.00 B | 35.18% |
2021-12-31 | โน17.01 B | -6.65% |
2020-12-31 | โน18.22 B | -2.42% |
2019-12-31 | โน18.68 B | -18.6% |
2018-12-31 | โน22.94 B | 145.38% |
2017-12-31 | โน9.35 B | 6.23% |
2016-12-31 | โน8.80 B | -24.57% |
2015-12-31 | โน11.67 B | -10.48% |
2014-12-31 | โน13.03 B | 35.31% |
2013-12-31 | โน9.63 B | 44910.67% |
2012-12-31 | โน21.4 M | -93.79% |
2011-12-31 | โน0.34 B |